Last reviewed · How we verify
oral liposomal iron
Oral liposomal iron, developed by the Federal University of Juiz de Fora, is a marketed product with a key composition patent expiring in 2028. The drug's unique liposomal delivery system offers a potential competitive advantage in improving absorption and reducing side effects. The primary risk is the lack of revenue data and key trial results, which may limit its commercial appeal and investor confidence.
At a glance
| Generic name | oral liposomal iron |
|---|---|
| Also known as | ferric pyrophosphate, Sideral forte |
| Sponsor | Federal University of Juiz de Fora |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Liposomal vs Conventional Oral Iron After Sleeve Gastrectomy (NA)
- Liposomal Iron 30 mg Supplement in Non-anemic Pregnant Females
- Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients (PHASE4)
- Comparative Study Between Oral Liposomal Iron,Iron Supported Lactoferrin and IV Iron Dextran in CKD Children (PHASE4)
- Efficacy and Safety of Liposomal Lactoferrin in COVID-19 Patients With Mild-to-Moderate Disease and in COVID-19 Asymptomatic Patients (PHASE2, PHASE3)
- FLIPS: Ferfer Liposomal Iron Performance Study (PHASE4)
- Anemia in Inflammatory Bowel Disease (PHASE4)
- Endovenous Versus Liposomal Iron in CKD (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- oral liposomal iron CI brief — competitive landscape report
- oral liposomal iron updates RSS · CI watch RSS
- Federal University of Juiz de Fora portfolio CI